Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12140987 | 0.79 | SHBG (0.53) | SHBGCYP3A4 | |
| SCHEMBL4227246 | 0.79 | SHBG (0.53) | SHBGCYP3A4 | |
| SCHEMBL4220412 | 0.79 | SHBG (0.53) | SHBGCYP3A4 | |
| SCHEMBL11960923 | 0.79 | SHBG (0.53) | SHBGCYP3A4 | |
| SCHEMBL16988319 | 0.71 | ESR1 (0.37) | SHBGCYP3A4MEN1ALDH1A1KMT2A | |
| SCHEMBL16988571 | 0.71 | ESR1 (0.37) | SHBGCYP3A4MEN1ALDH1A1KMT2A | |
| SCHEMBL16987905 | 0.69 | SHBG (0.34) | SHBGCYP3A4 | |
| SCHEMBL16988659 | 0.68 | ESR1 (0.42) | SHBG | |
| SCHEMBL4232429 | 0.68 | ESR1 (0.42) | SHBG | |
| SCHEMBL15195626 | 0.68 | SHBG (0.59) | SHBGCYP3A4MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135534-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20200131148-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| WO-2018111315-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135534-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | SHBG 1175/4885CYP3A4 801/4885MEN1 4404/4885 |
| US-20200131148-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | SHBG 1175/4885CYP3A4 801/4885MEN1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.